U.S. Food and Drug Administration recently issued the following announcement.
Abciximab (ReoPro) Injection
Status: Currently in Shortage
»Date first posted: 04/11/2018
»Therapeutic Categories: Cardiovascular
Janssen Biotech, Inc. (New 04/11/2018)
Company Contact Information: 800-586-7736
Presentation: 2mg/mL (NDC 57894-200-01)
Availability and Estimated Shortage Duration: Availability and estimated shortage duration: TBD
Shortage Reason (per FDASIA): Requirements related to complying with good manufacturing practices
Original source can be found here.